Pharming Group to report second quarter and first half 2024 financial results on August 1

Rhea-AI Summary

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced it will report its preliminary (unaudited) second quarter and first half 2024 financial results on Thursday, August 1, 2024. The report will cover the period ended June 30. The company will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on the same day.

Interested parties can participate in the conference call by registering in advance. Upon registration, dial-in information and a unique PIN will be provided for call access. The company will only take questions from dial-in attendees. Additionally, a live webcast of the presentation will be available for those who prefer to watch online. Both the conference call and webcast require pre-registration through the provided links.

Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.

Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on August 1, 2024.

To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

Conference call registration:

Please note, the Company will only take questions from dial-in attendees.

https://register.vevent.com/register/BI92328f52b76d43d394cacc1c2ba94ac4

To watch the live webcast, please register in advance using the link below.

Webcast registration:

https://edge.media-server.com/mmc/p/awvi6h6a/

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Attachment

• Pharming Group to report 2Q24_1H24 results_EN_18JULY24

FAQ

When will Pharming Group report its Q2 and H1 2024 financial results?

Pharming Group will report its preliminary (unaudited) second quarter and first half 2024 financial results on Thursday, August 1, 2024.

What period will Pharming's Q2 and H1 2024 financial results cover?

The financial results will cover the period ended June 30, 2024.

What time is Pharming's Q2 and H1 2024 financial results presentation scheduled for?

Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on August 1, 2024.

How can investors participate in Pharming's Q2 and H1 2024 financial results conference call?

Investors can participate by registering in advance through the provided link. Once registered, they will receive dial-in information and a unique PIN for call access.

Will there be a webcast available for Pharming's Q2 and H1 2024 financial results presentation?

Yes, a live webcast will be available. Interested parties need to register in advance using the provided webcast registration link.